首页> 美国卫生研究院文献>Oncotarget >Validation of the Memorial Sloan Kettering Cancer Center nomogram to predict disease-specific survival in a Chinese gastric cancer population receiving postoperative chemoradiotherapy after an R0 resection
【2h】

Validation of the Memorial Sloan Kettering Cancer Center nomogram to predict disease-specific survival in a Chinese gastric cancer population receiving postoperative chemoradiotherapy after an R0 resection

机译:斯隆·凯特琳纪念癌症中心纪念图诺模图的验证可预测R0切除术后接受放化疗的中国胃癌人群的疾病特异性生存率

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The widely validated Memorial Sloan Kettering Cancer Center (MSKCC) nomogram for gastric carcinoma (GC) was developed based on patients who received R0 resection only. The purpose of the current study was to assess the performance of this nomogram in Chinese patients who received postoperative chemoradiotherapy (CRT) after an R0 resection for GC. From 2006 to 2015, the clinical data of 150 eligible patients were retrospectively collected from the Fudan University Shanghai Cancer Center (FUSCC) and used for external validation. The nomogram was validated by means of the concordance index (CI) and a calibration plot. The CI for the nomogram was 0.657, which was lower than the CI of the nomogram for patients who received surgery alone (0.80). In the calibration plot, the gap between the observed and the predicted survival gradually increased as the predicted 5-year disease-specific survival (DSS) decreased. Thus the MSKCC nomogram for GC significantly underestimated the survival of patients in the FUSCC cohort, especially the survival of patients whose predicted 5-year DSS was less than 50%. The current study indicates the potential for the nomogram to be developed as an ideal tool to identify target patients for postoperative CRT.
机译:胃癌(GC)的经过广泛验证的纪念斯隆凯特琳癌症中心(MSKCC)列线图是根据仅接受R0切除的患者开发的。本研究的目的是评估R0切除GC后接受术后放化疗(CRT)的中国患者的诺模图表现。从2006年至2015年,从复旦大学上海癌症中心(FUSCC)回顾性收集了150名符合条件的患者的临床数据,并将其用于外部验证。通过一致性指数(CI)和标定图验证了列线图。诺模图的CI为0.657,低于仅接受手术的患者的诺模图的CI(0.80)。在校准图中,随着预测的5年疾病特异性生存率(DSS)降低,观察到的生存率与预测生存率之间的差距逐渐增大。因此,GC的MSKCC列线图显着低估了FUSCC队列中患者的存活率,尤其是预测的5年DSS低于50%的患者的存活率。当前的研究表明,可能将诺模图开发为确定术后CRT目标患者的理想工具。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号